U.S. spot Bitcoin and Ether exchange-traded funds (ETFs) experienced combined net outflows of $538.3 million on Monday, with Bitcoin ETFs accounting for $398.6 million and Ether ETFs $139.7 million. This marks a continuation of withdrawals, with Bitcoin ETFs seeing a second consecutive day of large outflows and Ether ETFs extending a six-day streak of net outflows. The recent Bitcoin withdrawals follow a brief period of inflows in late October, while Ether funds have been in decline since late October. These significant outflows highlight ongoing investor caution or shifting sentiment in the crypto ETF market.
The U.S. spot Bitcoin and Ether ETFs outflows provide context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Nov 03, 2026 12:21 WIB: out of 50 major cryptocurrencies priced on Pluang, only 5 rose while 44 fell. Among notable movers, SAND dropped 5.11% to Rp795 with a near-even buy-sell split, contrasting sharply with ONE's 95% sell order activity and 5.08% price decline to Rp20, and COTI's 5.00% fall to Rp178 with a 57% sell order share. This shows varied investor behavior across assets amid broad declines.
ZYT officially introduced its Prax Drive System™, a commercial vehicle technology, partnering with leading Chinese truck makers like XCMG, Shacman, and Sinotruk. The system supports heavy trucks, buses, light trucks, and vans, with production underwa...
Yaoyao, the Asia-Pacific growth lead for the Solana Foundation, has announced her departure after three and a half years with the organization. She joined in 2023 and played a key role in expanding Solana's presence in Greater China, including foundi...
On November 2, spot Bitcoin exchange-traded funds (ETFs) experienced net outflows totaling $399 million, primarily driven by Blackrock's IBIT fund which alone lost $405 million. Despite this, Fidelity's FBTC fund recorded the largest inflow of $6.68 ...
The Rose Income Garden portfolio highlights VICI Properties and W. P. Carey as the most undervalued dividend raisers for October, with VICI offering a 7.52% yield and expanding beyond Las Vegas. The portfolio, which includes 69 investments across all...
ARS Pharmaceuticals is rated Buy as its current stock price undervalues its pipeline potential despite commercial challenges. Its main product, neffy, an intranasal epinephrine spray, faces slow market adoption and insurance issues but holds promise ...
